HDAC9 and cancer: Inspired by the synergistic effects of tubulin and HDAC inhibitors in dual targeting cancer therapy and the interaction between proteins, some o-aminobenzamide-based dual HDAC/tubulin inhibitors have been reported, which could target tumor tissues more accurately, thus enhancing their efficacy and improving the antitumor effects [257].